Breaking News

SNBL USA Appoints Field Technical Director

June 28, 2013

Templin to provide scientific, regulatory guidance for preclinical programs

Michael Templin, Ph.D., DABT, has been named field technical director for SNBL USA.  Dr. Templin, based on the west coast, will work closely with business development and internal scientific teams to provide SNBL USA’s clients with scientific and regulatory guidance to support their preclinical development programs. He joins the company from Marina Biotech where he served as chief technology officer.
 
Dr. Templin is a board-certified toxicologist with more than 15 years of experience in preclinical and early clinical drug development. He has extensive experience in small molecules, biologics, peptides and multiple classes of nucleic acid-based drugs, and has worked in multiple therapeutic areas including cancer, inflammation, cardiovascular, metabolic and antivirals. He also has experience with nonhuman primate programs, including design, oversight and interpretation of research and GLP studies for INDs, NDAs and ex-U.S. submissions.
 
“This is an exciting time for SNBL USA and our clients,” said Mark Crane, vice president of business development. “Dr. Templin’s exceptional preclinical and early clinical background, along with his technical expertise and outstanding communication skills, will significantly enhance the benefits in working with SNBL USA.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important